While cancer drug prices have mostly outpaced median survival gains, prices have been rising mostly in tandem with mean survival gains, a recent study published in Value in Health suggests.
“This suggests that when accounting for longer-term survival gains, the benefits of new drugs are roughly keeping pace with their costs, despite rapid cost growth,” the authors write.
Researchers evaluated data on newly-approved cancer drugs between 1995-2017.
To read the article in Value in Health, click here. (Membership required)